Caris Life Sciences to Present Initial Study Results for Blood-Based Prostate Cancer Test at AACR Annual Meeting

IRVING, Texas, March 27, 2019 /PRNewswire/ -- Caris Life Sciences^®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that it will present initial validation of a blood-based prostate cancer assay at the American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019, at the Georgia World Conference Center in Atlanta. Caris President and Chief Scientific Officer Dr. David Spetzler will detail the results of a study on the assay during his oral presentation, "Poly-ligand Profiling of Plasma Samples as a Potential Predictor of Prostate Biopsy Results," on Monday, April 1, from 4:35 - 4:50 p.m. Eastern in Room A315.

Caris developed the new blood-based prostate cancer test as part of an effort to improve the accuracy of prostate cancer screening and reduce the need for unnecessary prostate biopsies. With its proprietary profiling platform, ADAPT Biotargeting System™, the company used single stranded oligonucleotide (ssODN) libraries to perform poly-ligand profiling on plasma exosomes from men scheduled for biopsy to classify those with or without a subsequent diagnosis of prostate cancer. Results suggest that poly-ligand profiling may provide an additional approach to stratify men with suspicious PSA levels for prostate biopsies.

"We are encouraged by the results of this study, which indicate that a blood test has the potential to accurately identify prostate cancer prior to an invasive biopsy," said Dr. Spetzler. "ADAPT is advancing diagnostics, and we hope that with further study, prostate cancer screenings will be made easier and less invasive by using a blood-based approach." 

The ADAPT Biotargeting System™ is an innovative and versatile unbiased profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics. It can measure thousands of protein aberrations and is being used to develop early cancer detection assays, discover novel drug targets, and characterize protein differences in cancers. 

In addition to Dr. Spetzler's oral presentation, Caris scientists and collaborators, comprised of experts from leading cancer centers around the world, will present four poster presentations at the AACR Annual Meeting: 

• "Spectrum of solid malignancies associated with mutations in CYLD gene"
• Monday, April 1, 8:00 a.m. - 12:00 p.m. Eastern, Section #34, Board #13
• Authors: Michelle Ellis, Jeff Swensen, Zoran Gatalica, Caris Life Sciences
• "Discovery of low abundance colorectal cancer related biomarkers by the ADAPT Biotargeting System™" 
• Tuesday, April 2, 8:00 a.m. - 12:00 p.m., Section #20, Board #12
• Authors: Tassilo Hornung, Jelena Zarkovic, Michelle Kassner, Matthew Rosenow, Mark R. Miglarese, David Spetzler, Caris Life Sciences; Günter Mayer, Michael Famulok, University of Bonn
• "Co-occurring mutations in recurrent/persistent Head and Neck Squamous Cell Carcinoma (HNSCC) patients"
• Tuesday, April 2, 1:00 - 5:00 p.m., Section #21, Board #16,
• Authors: Alok R. Khandelwal, Tara Moore-Medlin, Xiaohui Ma, Abhijit Gundale, LSU Health-Shreveport; Kelsey Poorman, Michelle Winerip, Caris Life Sciences; Ronald Horswell, San Chu, Pennington Biomedical Research Center
• "Relationship between protein biomarkers of potential chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in patients with cancer"
• Wednesday, April 3, 8:00 a.m. - 12:00 p.m., Section #21, Board #11
• Authors: Mina Nikanjam, Razelle Kurzrock, University of California at San Diego; David Arguello, Zoran Gatalica, Caris Life Sciences; Donald A. Barkauskas, University of Southern California, Los Angeles

Learn more about Caris at Booth #4437 in the AACR Exhibit Hall. 

About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Caris is also advancing precision medicine with Next Generation Profiling™ that combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System™, with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS). 

Caris Life Sciences Media Contact
Srikant Ramaswami
Vice President, Chief Communications Officer
[email protected] 
+1-214-769-5510

View original content to download multimedia:http://www.prnewswire.com/news-releases/caris-life-sciences-to-present-initial-study-results-for-blood-based-prostate-cancer-test-at-aacr-annual-meeting-300819365.html

SOURCE Caris Life Sciences